실적분석 2026년 8월 13일

Aveanna Healthcare ($AVAH) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat, Full-Year Guidance Raised

Earnings Scorecard

Revenue: $671 million (+13.7% YoY, vs. $639 million consensus) ✅ Beat

EPS: Adjusted $0.22 (vs. $0.17 consensus) ✅ Beat

Guidance: Raised — 2026 revenue of at least $2.68 billion and adjusted EBITDA of at least $365 million (prior: revenue $2.63–2.65 billion, EBITDA $338–342 million)

Stock Reaction: After-hours +12.49% ($10.18) — as of 08-13 KST 20:57

The Positives

Revenue beat: Q2 revenue of $671 million came in roughly 5% above the $639 million consensus

Adjusted EPS strength: Adjusted diluted EPS of $0.22 topped the $0.17 consensus

Full-year guidance raised: Revenue lifted to at least $2.68 billion and adjusted EBITDA to at least $365 million

Organic expansion drove the results, with all three segments posting growth. The pediatric and adult home nursing-led segment accounted for a particularly large share of the revenue increase. Free cash flow generation in the first half also confirmed that growth and cash creation are advancing in tandem.

The Negatives

Gross margin compression: Gross margin of 32.6% narrowed by 3.2 percentage points from 35.8% a year earlier

Adjusted EBITDA margin contraction: Adjusted EBITDA margin of 14.2% slipped from 15.0% in the prior-year period

Heavy debt load: Total borrowings of $1.483 billion translate into high leverage relative to net income

Revenue grew, but margin erosion from cost pressure is a real blemish. Medicaid and Medicare reimbursement changes and labor supply dynamics are structural risks inherent to the home-care industry. The sizable debt pile also leaves the company sensitive to shifts in interest rates and borrowing terms.

What Management Said

The CEO and CFO attributed the results to organic growth across all three segments and to the company's preferred-payor and government-policy strategy. They explained that confidence in the first-half performance and outlook led them to raise full-year revenue and adjusted EBITDA guidance.

Market Reaction and What to Watch Next

Beats on both revenue and adjusted EPS, combined with a raised full-year outlook, reaffirmed the home-care growth narrative and drew buyers into the stock.

It remains to be seen whether the company can deliver on the raised full-year revenue and adjusted EBITDA floor.

Whether the gross margin decline is transitory or reflects persistent labor and reimbursement pressure will be a key question for the next quarter.

Integration outcomes from the Family First acquisition and the durability of free cash flow generation are the central points to monitor.